4/6/2017

Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register

ORION CORPORATION         STOCK EXCHANGE RELEASE 6 APRIL 2017 at 9.00 EET             
         
Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register

The amendments of Section 5 and the first paragraph of Section 9 of the Articles of Association of Orion Corporation in accordance with the decision by the AGM held on 22 March 2017 have been entered in the Trade Register. The current Articles of Association are available on the company's website in the address www.orion.fi/articles-of-association. The decisions of the AGM were published in a Stock Exchange Release on 22 March 2017.

Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 50 966 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.